![](https://etira.life/wp-content/uploads/2024/06/image-495x400.jpeg)
Breakthroughs that
See what others are saying about Etira and our innovations
![](https://etira.life/wp-content/uploads/2024/06/image-495x400.jpeg)
![](https://etira.life/wp-content/uploads/2024/05/Etira-Image-for-Press-Release-495x400.jpg)
ERX-315 SUBMITTED FOR HREC APPROVAL
NewsDallas, TX – May 14th, 2024 - Etira is pleased to announce the submission of the regulatorydocuments for approval of administration of its breakthrough oncology drug ERX-315 to theHuman Research Ethics Committee (HREC) in Australia.…
![](https://etira.life/wp-content/uploads/2024/05/Unknown-495x400.jpeg)
ERX-208 potency in Ovarian Cancer
NewsSan Diego, CA. April 10, 2024: Etira founder Dr Ratna Vadlamudi’s laboratory presents comprehensive data on the activity of ERX-208 in ovarian cancer. ERX-208 is active against all four molecular subtypes of ovarian cancer and its activity…
![](https://etira.life/wp-content/uploads/2024/01/image-495x400.png)
Targeting LIPA in ovarian cancer
NewsDallas, TX. January 24, 2024: We are pleased to present a manuscript in Cancers from the laboratory of Etira founder Dr. Ratna Vadlamudi. The data presented show that ERX-41 targets LIPA in ovarian cancer and is effective against all 4 subtypes…
![](https://etira.life/wp-content/uploads/2024/02/image-1-495x400.jpeg)
ERX-315 introduced at SABCS 2023
NewsSan Antonio, TX. December 7, 2023: Etira is pleased to present the data with its lead compound ERX-315 that cause catastrophic levels of ER stress, resulting in breast cancer cell death, and that can successfully function against multiple forms…
![](https://etira.life/wp-content/uploads/2023/10/image-495x400.png)
Independent validation of LIPA as a molecular target in TNBC
NewsDallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.
The authors conclude that LIPA-activity is a novel…
Where to find us
Boston Office:
75 Kneeland Ave, 14th Floor
Boston. MA. 02111
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247